FDA Approves Strensiq for Alexion Pharma (ALXN); Oppenheimer Reiterates Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Baird Remains Bullish on Alexion Pharma (ALXN) as FDA Approves Strensiq
October 27, 2015 9:14 AM EDTBaird reiterated an Outperform rating and $221.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following Strensiq's FDA approval for hypophosphatasia. The company plans to use a sales force approximately double that at Soliris launch, to promote both Strensiq and Kanuma (PDUFA: December 8) along with Medical... More
Alexion Pharma (ALXN) to Resume Trading at 4:15 PM ET
October 23, 2015 3:57 PM EDTAlexion Pharma (NASDAQ: ALXN) to Resume Trading at 4:15 PM ET
... MoreFDA Approves Alexion's (ALXN) Strensiq to Treat Perinatal, Infantile and Juvenile-Onset HPP
October 23, 2015 3:40 PM EDT(Updated - October 23, 2015 3:45 PM EDT)
Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
HPP is a rare, genetic, progressive, metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to severe disability and life-threatening complications. It is characterized by defective bone mineralization that can lead to rickets and softening of the bones that result in skeletal abnormalities. It can also cause complications such as profound muscle weakness with loss of mobility, seizures, pain, respiratory failure and... More
Alexion Pharma (ALXN) halted with news pending
October 23, 2015 3:38 PM EDTAlexion Pharma (NASDAQ: ALXN) trading halted with news pending.
... More